Stockscreener 앱 받기
0.3677
0.99%
0.0036
시간 외 거래:
.37
0.0023
+0.63%
전일 마감가:
$0.3641
열려 있는:
$0.37
하루 거래량:
346.62K
Relative Volume:
0.60
시가총액:
$21.59M
수익:
-
순이익/손실:
$-123.46M
주가수익비율:
-0.142
EPS:
-2.59
순현금흐름:
$-104.11M
1주 성능:
+4.25%
1개월 성능:
-6.65%
6개월 성능:
-20.86%
1년 성능:
-80.44%
1일 변동 폭
$0.3566
$0.3781
1주일 범위
$0.34
$0.397
52주 변동 폭
$0.2601
$2.525
바이오아틀라 Stock (BCAB) Company Profile
명칭
Bioatla Inc
전화
858-558-0708
주소
11085 TORREYANA ROAD, SAN DIEGO
BCAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.3677 | 23.04M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오아틀라 Stock (BCAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 개시 | JMP Securities | Mkt Outperform |
| 2022-05-05 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-06-28 | 개시 | ROTH Capital | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | BTIG Research | Buy |
| 2021-01-11 | 개시 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | JP Morgan | Overweight |
| 2021-01-11 | 개시 | Jefferies | Buy |
모두보기
바이오아틀라 주식(BCAB)의 최신 뉴스
Exit strategy if you’re trapped in BioAtla Inc.Quarterly Trade Summary & Risk Managed Investment Signals - Newser
Can BioAtla Inc. rally from current levels2025 Support & Resistance & Capital Protection Trading Alerts - Newser
BioAtla downgraded to Market Perform from Outperform at Citizens JMP - MSN
Using data filters to optimize entry into BioAtla Inc.2025 Investor Takeaways & Reliable Volume Spike Alerts - Newser
BioAtla’s Earnings Call: Positive Clinical Progress Amid Financial Challenges - MSN
JMP Securities Reiterates “Market Perform” Rating for BioAtla (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Rating Lowered to Market Perform at Citizens Jmp - Defense World
How sentiment analysis helps forecast BioAtla Inc.Weekly Trend Summary & AI Powered Market Trend Analysis - Newser
BioAtla's BCAB Downgraded to Market Perform by JMP Securities - AInvest
Combining price and volume data for BioAtla Inc.Portfolio Return Report & Weekly High Momentum Picks - Newser
HC Wainwright Predicts BioAtla’s Q3 Earnings (NASDAQ:BCAB) - Defense World
BioAtla’s SWOT analysis: oncology biotech’s stock faces cash crunch - Investing.com
BioAtla stock downgraded by Citizens JMP on cash concerns - Investing.com Canada
Has BioAtla Inc. formed a bullish divergence [2025 Institutional Moves]AI Based Buy and Sell Signals - Newser
Will BioAtla Inc. see short term momentum [2025 Market Trends]Accurate Intraday Trading Signals - Newser
Why BioAtla Inc. stock attracts strong analyst attentionDay Trading Plan with Entry Risk Management - Newser
What technical models suggest about BioAtla Inc.’s comebackFree Portfolio Diversification Stock Ideas - Newser
Analysts Apply Wyckoff Model to BioAtla Inc. StockBuy Low Sell High Stock Watch Strategy in Focus - 선데이타임즈
BioAtla, Inc. (NASDAQ:BCAB) Q2 2025 Earnings Call Transcript - Insider Monkey
What makes BioAtla Inc. stock price move sharplyWatchlist Generator for Smart Money Signals - Newser
BioAtla Inc. stock trend outlook and recovery pathFree Stable Entry High Return Opportunities - Newser
Buy Signal for BioAtla Inc. Stock Key Technical Indicators to WatchFree Conservative Entry for High Return Setup - Newser
What institutional flow reveals about BioAtla Inc.Automated AI Forecast with Trading Alerts - Newser
BioAtla Inc. Testing Reversal Zone on Weekly ChartAI Trading Suggestions With Accuracy Focus Released - beatles.ru
Can BioAtla Inc. Outperform Peers After Recent PullbackFundamental + Technical Hybrid Stock Tips Shared - beatles.ru
Does BioAtla Inc. stock have upside surprise potentialDaily Breakout Recap Watch - sisaissue.com
BioAtla, Inc. Reports Q2 2025 Financial Results and Clinical Progress - TipRanks
Head-To-Head Review: Alzamend Neuro (NASDAQ:ALZN) & BioAtla (NASDAQ:BCAB) - Defense World
Sector ETF performance correlation with BioAtla Inc.Free Alpha Driven Watchlist With Alerts - Newser
Comparing BioAtla Inc. in custom built stock radarsFree Swing Setup With Technical Confirmation - Newser
BioAtla's Strategic Position in Immuno-Oncology and Partnership-Driven Growth - AInvest
BioAtla August 2025 slides: promising clinical data amid financial headwinds By Investing.com - Investing.com Nigeria
Earnings call transcript: Bioatla Q2 2025 misses EPS forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: Bioatla Q2 2025 misses EPS forecasts - Investing.com India
BioAtla August 2025 slides: promising clinical data amid financial headwinds - Investing.com
BioAtla Inc Reports Q2 2025 EPS of -$0.32, Missing Estimates; Net Loss at $18.7 Million - AInvest
BioAtla faces Nasdaq delisting over share price rule - MSN
BioAtla Inc (BCAB) Q2 2025 Earnings Call Highlights: Promising Clinical Progress Amid Financial ... By GuruFocus - Investing.com Canada
Bioatla Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : BioAtla, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
BioAtla, Inc. SEC 10-Q Report - TradingView
바이오아틀라 (BCAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.88%
자본화:
|
볼륨(24시간):